Because EGFR is overexpressed in up to 70% of ovarian cancers and is associated with poor prognosis, monoclonal anti-EGFR antibodies such as cetuximab have been added to paclitaxel and platinum-based agents in patients with recurrent ovarian cancer (9, 30). Here, EGFR is linked to ovarian carcinoma.